SITC Biotech Strategic Meeting at NYSE

SITC Biotech Strategic Meeting at the NYSE

Friday, June 27, 2025, from 8:30 A.M.–2 P.M. ET

Register Now

SITC Biotech InitiativeJoin the SITC Biotech CommunitySITC Biotech Virtual Programs

The 2025 NYSE Program is supported, in part, through the SITC Biotech Community Memberships of BioNTech and Numenos (supporters as of April 1, 2025).

This exclusive event will bring together experts, investors, and biotech innovators to discuss the future of T-cell engagers, China’s impact on IO clinical research, and strategic pathways for novel immunotherapy advancements.

Schedule

8–8:30 am ET

Arrivals and Breakfast

8:30–8:35 am ET

Welcome, Objectives, Introduction & SITC Biotech Committee Update

Zhen Su, MD, MBA – Marengo Therapeutics

8:35–9:05 a.m. ET

Navigating the Regulatory Framework for Novel IO Agents

Panel

  • Considerations for complex, novel therapies
  • How pharma companies are handling the current regulatory challenges
  • Understanding the AI Framework for monoclonal antibody discovery
  • What can we learn from engaging with entities outside the FDA like Medicines and Healthcare products Regulatory Agency (MHRA)
  • Exploring calls to action

Craig Tendler, MD – Janssen
Brad Loncar, BBA – BiotechTV

9:05 a.m.–9:45 a.m. ET

Tour of the Floor + Bell Ringing

9:45 a.m.–11 a.m. ET

Current State of the Field

15 Minute Presentation + 10 Minute Panel
Trends and data in the IPO market

  • Financing, investing, deal making of biotech innovation in immuno-oncology

Jeff Bockman, PhD – Lumanity
Daina M. Graybosch, PhD - Leerink Partner

Moderator: Alexandra Snyder, MD – Generate Biomedicines 

Current State of the Field

TCEs, Bi-specifics & Beyond: Understanding their rise.

  • How to improve the therapeutic index of these novel agents, including re-agents and combination approaches.

Arun Balakumaran, MD, PhD – Pfizer
Cedrik Britten, MD – Immatics
Jane Healy, MD, PhD – Merck 

Moderator: Beverly Lu, PhD – Yosemite 

Current State of the Field

Cell Therapy Inflection Points

  • Navigating difficult times, identifing value, and recognizing key inflection points (clinical and financial) 

Ken Drazan – Arsenal Bio
Brad Loncar, BBA – BiotechTV
Scott Rodig, MD, PhD – Brigham & Women's Hospital, Inc.

Moderator: Kasia Urbanska – Bristol Meyers Squibb

11 a.m.–12:45 p.m. ET

China's growing influence on the biotech industry: How can modern innovation address the challenge of finding a "needle in a haystack"?

Panel
Beyond "Me Too" biologics

  • How China is now refining biologics with unique, sophisticated properties.

Leon 'Jun' Tang, PhD – In Science We Trust
Bing Yuan, PhD – OnCusp

Panel
Cost-effective drug development;

  • Scientific engineering and the acceleration of clinical trials from different perspectives including CMCs, CEOs, CMOs, and Tech Ops

Sherry Gu, PhD – WuXi
Geoffrey Kim, MD – Pi Health
Sammi Tang, PhD – Astellas

Panel
PD-1/VEGF bispecifics

  • Exploring how multi-specific pharma oncology can be fine-tuned for unique applications in IO.
  • How can the U.S. remain competitive?
  • How should target combinations be screened effectively?

Jane Healy, MD, PhD – Merck
Daina M. Graybosch, PhD  –  Leerink Partners  
Ellie Im, MD – Cresent Biopharma

12:45 p.m.–1:15 p.m. ET

Break/Working Lunch

1:15 p.m.–1:55 p.m. ET

Partnership Session; Hypothesis-driven approach to mapping novel biological pathways and strategies for acquiring assets.

Presentation
The Story of BioNTech's ADC Investment
Holger Kissel, PhD – BioNTech SE

Presentation

Panel
Holger Kissel, PhD – BioNTech SE

1:55 p.m.–2 p.m. ET

Closing Remarks and Synthesis

Zhen Su, MD, MBA – Marengo Therapeutics

The 2025 SITC NYSE Program focuses on cutting-edge immunotherapy agents in biotech development. The program begins with an analysis of IPO trends, followed by panel discussions on the current state and future potential of T Cell Engagers, Bi-specifics & combination therapies.

These discussions explore their rise and strategies to optimize therapeutic outcomes. A panel on Cell Therapy examines navigating challenges and maximizing value.

Part two of the program highlights China's impact on biotech, addressing innovative approaches to biologics beyond "Me Too" products. Topics include cost-effective drug development, scientific engineering, and accelerated clinical trials from diverse perspectives including CMCs, CEOs, CMOs, and Tech Ops. 

Insights from PD-1/VEGF bispecifics and international data inform discussions on optimizing multi-specific oncology applications in immunotherapy. The program concludes with a partnership session focusing on mapping novel biological pathways and asset acquisition strategies.

Thank you to our organizers

Emy Chen, PhD

Emy Chen, PhD 
Dana Farber Innovation Institute

Kristen Hege, MD

Kristen Hege, MD
Board Member, Mersana, Adaptimmune, Kelonia and EvolveImmune

David Kaufman, MD, PhD

David Kaufman, MD, PhD
Third Rock Ventures

Holger Kissel, PhD

Holger Kissel, PhD
BioNTech SE

Beverly Lu, PhD

Beverly Lu, PhD
Yosemite

Alexandra Snyder, MD

Alexandra Snyder, MD
Generate Biomedicines

Zhen Su, MD, MBA

Zhen Su, MD, MBA
Marengo Therapeutics

Kasia Urbanska, PhD

Kasia Urbanska, PhD
Bristol Myers Squibb

Registration Rates

Category Early Rates
Ends at 11:59 pm on May 4		 Regular Rates
Ends at 11:59 pm on June 11
Member
Regular		 $200 $250
Member
Industry		 $400 $450
Member
Student		 $50 $100
Non-Member
Regular		 $400 $450
Non-Member
Industry		 $800 $850
Non-Member
Student		 $100 $150

Travel and Accommodations

All attendees and panelists are asked to arrange for their own travel and accommodations.There is no designated hotel block for this event. Registrants will be provided a list of recommended hotels with special NYSE rates.

Cancellation and Refund Policy

Refund requests should be submitted in writing to the SITC office at events@sitcancer.org by June 11, 2025. A $25 processing fee will be charged for all paid registrations. All refunds will be processed within two weeks of receipt. No refunds will be granted if cancellation is received after June 11, 2025. 

Covid-19 Measures

At SITC programs, our goal is to have a safe and meaningful in-person experience. SITC will refer to the CDC COVID-19 Community Levels to guide health precautions for in-person meetings. In addition, SITC strongly recommends that in-person meeting attendees take the following precautions: 

  • Stay up to date with COVID-19 vaccinations
  • Take a rapid COVID test prior to attending a meeting and do not attend in person if you test positive
  • Do not attend the meeting if you have symptoms that could be consistent with a “cold” or any other respiratory infection and leave the meeting if you develop such symptoms
  • Wear a mask in crowded indoor settings
  • Follow all health and safety protocols as required by SITC and local and state health departments
  • Review current CDC and applicable local guidance for protecting yourself from COVID-19.

Attendees will have access to the meeting content online if they are unable to attend in person due to illness or a positive COVID test. For hybrid programs, attendees can change from in-person to online-only registration by contacting events@sitcancer.org.

Registered attendees will be notified in advance of any changes to precautions, recommendations or requirements for a SITC meeting.

Photography Policy and Meeting Code of Conduct 

You can read the SITC Photography Policy and Meeting Code of Conduct on the SITC Policies Page.

Questions

If you have questions about this program, please contact education@sitcancer.org.